BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Celgene Corporation (CELG), Nuvilex on Similar Path in Fight Against Pancreatic Cancer


3/5/2013 9:15:00 AM

NEW YORK, NY--(Marketwire - March 05, 2013) - Two biotechnology companies, NASDAQ's Celgene, Corp. and Nuvilex, Inc. (OTCQB: NVLX), are hot on the heels of a third biotech that has dominated the pancreatic drug market since 1996. Stock House Group, a research and content development investor relations firm, takes a look at the amazing results that both are delivering and tells a story that the NYSE's Eli Lilly and Company should start giving a little more attention.

In late January, those with advanced stage pancreatic cancer received some good news when Celgene, Corp., an international biotechnology company, announced the results of its large scale phase III trial at the 2013 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO), held in San Francisco.

Pancreatic cancer is difficult to diagnose and treat until it is at an advanced stage. Survival of patients with advanced, inoperable pancreatic cancer is usually only several weeks or a few months. The National Cancer Institute estimates that, in the U.S. alone, 45,220 new cases of pancreatic cancer will be diagnosed in 2013 and that 38,460 deaths will be attributable to the dreaded disease this year.

But, like two prize fighters, a pair of biotech companies, is steadfast in the battle against a common enemy -- pancreatic cancer. Both have presented astounding results that leave one to think, we may be extremely close to turning the corner in the fight against this brutal disease.

David and Goliath Strengthen Hand vs. Opponent
One is a Goliath in the biotech world, leaving the other to take on the role of David as a much smaller biotech, but for those who suffer with pancreatic cancer, they don't see size, they see results. And, the results these two companies are delivering are providing much needed hope to patients, interestingly though, from two completely different approaches.

Read the full feature news article at www.stockhousegroup.com/features

About Stock House Group
Stock House Group is a full service Investment Relations firm specializing in Awareness, Research, and Content Development. The firm offers a platform to CEOs to develop their story through the press, Research Reports, and CEO Interviews. At the same time, we are building a library of Research for Investors to use while doing their due diligence on micro, small and large cap stocks.


Contact:
Stock House Group
www.stockhousegroup.com
Email Contact
646-397-4020



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES